

PRODUCT INFORMATION



SARS-CoV-2 Spike Glycoprotein Polyclonal Antibody

Item No. 32503

Overview and Properties

| | |
|----------------------------|---|
| Contents: | This vial contains 50 or 100 µl of antigen-affinity purified polyclonal antibody. |
| Synonyms: | 2019-nCoV Surface Glycoprotein, COVID-19 Surface Glycoprotein, SARS-CoV-2 Surface Glycoprotein, Severe Acute Respiratory Syndrome Coronavirus 2 Spike Glycoprotein |
| Immunogen: | Recombinant SARS-CoV-2 spike glycoprotein S1+S2 extracellular domain (His-tagged) |
| Cross Reactivity: | (+) SARS-CoV spike glycoprotein RBD, SARS-CoV spike glycoprotein S1 subunit, SARS-CoV-2 spike glycoprotein RBD, SARS-CoV-2 spike glycoprotein S1 subunit |
| Species Reactivity: | (+) SARS-CoV-2 |
| Form: | Liquid |
| Storage: | -80°C (as supplied) |
| Stability: | ≥1 year |
| Storage Buffer: | 0.2 µm filtered solution in PBS |
| Host: | Rabbit |
| Isotype: | IgG |
| Applications: | ELISA and Western blot (WB); the recommended starting dilution is 1:5,000-1:10,000 for ELISA and 1:1,000-1:5,000 for WB. Other applications were not tested, therefore optimal working concentration/dilution should be determined empirically. |

WARNING
THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA
This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY
Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 03/08/2023

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM

PRODUCT INFORMATION



Description

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an enveloped positive-stranded RNA virus, a member of the *Betacoronavirus* genus, and the causative agent of COVID-19.¹⁻⁵ The SARS-CoV-2 surface glycoprotein, also known as the spike glycoprotein, is located on the outer envelope of the virion.¹ It is composed of an S1 and S2 subunit divided by a furin S-cleavage site not found in other SARS-CoVs.^{6,7} The S1 subunit contains the receptor-binding domain (RBD), which binds to the carboxypeptidase angiotensin-converting enzyme 2 (ACE2), and the S1 and S2 subunits are cleaved by the protease TMPRSS2 to facilitate viral fusion with the host cell membrane.⁸⁻¹⁰ Cayman's SARS-CoV-2 Spike Glycoprotein Polyclonal Antibody can be used for ELISA and Western blot (WB) applications. The antibody recognizes the spike glycoprotein from SARS-CoV-2.

References

1. Kandeel, M., Ibrahim, A., Fayez, M., *et al.* From SARS and MERS CoVs to SARS-CoV-2: Moving toward more biased codon usage in viral structural and nonstructural genes. *J. Med. Virol.* **92**(6), 660-666 (2020).
2. Lu, R., Zhao, X., Li, J., *et al.* Genomic characterisation and epidemiology of 2019 novel coronavirus: Implications for virus origins and receptor binding. *Lancet* **395**(10224), 565-574 (2020)
3. Meo, S.A., Alhowikan, A.M., Al-Khlaiwi, T., *et al.* Novel coronavirus 2019-nCoV: Prevalence, biological and clinical characteristics comparison with SARS-CoV and MERS-CoV. *Eur. Rev. Med. Pharmacol. Sci.* **24**(4), 2012-2019 (2020).
4. Klok, F.A., Kruip, M.J.H.A., van der Meer, N.J.M., *et al.* Incidence of thrombotic complications in critically ill ICU patients with COVID-19. *Thromb. Res.* **191**, 145-147 (2020).
5. Yang, F., Shi, S., Zhu, J., *et al.* Analysis of 92 deceased patients with COVID-19. *J. Med. Virol.* **92**(11), 2511-2515 (2020).
6. Liu, Z., Xiao, X., Wei, X., *et al.* Composition and divergence of coronavirus spike proteins and host ACE2 receptors predict potential intermediate hosts of SARS-CoV-2. *J. Med. Virol.* **92**(6), 595-601 (2020).
7. Walls, A.C., Park, Y.-J., Tortorici, M.A., *et al.* Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. *Cell* **181**(2), 281-292 (2020).
8. Hoffmann, M., Kleine-Weber, H., Schroeder, S., *et al.* SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. *Cell* **181**(2), 271-280 (2020).
9. Yan, R., Zhang, Y., Li, Y., *et al.* Structural basis for the recognition of the SARS-CoV-2 by full-length human ACE2. *Science* **267**(6485), 1444-1448 (2020).
10. Wrapp, D., Wang, N., Corbett, K.S., *et al.* Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. *Science* **367**(6483), 1260-1263 (2020).

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM